Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/24/24 | 8-K | Current report filing |
|
   |
6 |
| 07/15/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 07/15/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
8 | |
| 07/11/24 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 07/10/24 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/05/24 | S-3 | Registration statement for specified transactions by certain issuers |
|
15 | |
| 06/20/24 | 8-K | Current report filing |
|
|
24 |
| 06/14/24 | 8-K | Current report filing |
|
|
19 |
| 06/13/24 | 8-K | Current report filing |
|
|
4 |
| 05/22/24 | 8-K | Current report filing |
|
|
3 |
